Orthocell's Chair John Van der Wielen highlights the swift progress in the US market for the company's nerve repair product, Remplir. Following FDA clearance, Orthocell has secured four US distributors, prioritising independent distributors to speed up market entry and reduce costs.
John shares plans to engage ten distributors by June, confident due to Orthocell's (ASX: OCC) proactive approach in the US nerve repair market, estimated to be significantly larger than Australia's. He discusses anticipated sales and revenue growth this quarter.
Orthocell (ASX: OCC) is undeterred by potential US tariff risks, stating that Remplir, as a niche life-changing product, is less likely affected. Tariffs target high-volume pharmaceuticals. With robust clinical standards and a trade surplus, John sees minimal impact on Orthocell from US trade policies.
OCC Price at posting:
$1.25 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)